Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate development, innovation and establishment of adoptive cellular therapy clinical trials for treatment of pediatric patients (18 years or younger) with solid tumors. Specifically, UG3 phase of the awards will support preclinical, translational and investigational new drug (IND)-enabling studies that lay groundwork for UH3 early-stage clinical trials testing adoptive immune cell therapies in pediatric patients with solid tumors. The successful applications will add to the newly established Cancer Adoptive Cellular Therapy (Can-ACT) Network, dedicated to developing innovative cell therapy approaches for the treatment of solid tumors in pediatric and adult cancer patients. This Network of investigators will, through novel and collaborative approaches to preclinical and translational studies, bring new cell therapy products into clinical trials.
Deadlines:
-
Letter of Intent Due Date(s): 30 days prior to application due date
-
Application Due Date: March 6, 2024
RFA-CA-24-021 Expiration Date March 07, 2024
Application budgets may not exceed $900,000/year in direct costs for the UG3 phase and $1,500,000/year in direct costs for the UH3 phase (excluding sub-award F&A costs) and must reflect the actual needs of the proposed project.
The scope of the proposed project should determine the project period. The maximum project period is two years for UG3 phase and three years for UH3 phase.